Toxin-Specific Antibodies for the Treatment of Clostridium difficile: Current Status and Future Perspectives

• Main Authors: Greg Hussack, Jamshid Tanha
• Format: Article
• Language: English
• Published: MDPI AG 2010-05-01
• Series: Toxins
• Subjects: Clostridium difficile; Clostridium difficile-associated disease; toxin; antibody; single-domain antibody; neutralization; therapy
• Online Access: http://www.mdpi.com/2072-6651/2/5/998/

Therapeutic agents targeting bacterial virulence factors are gaining interest as non-antibiotic alternatives for the treatment of infectious diseases. Clostridium difficile is a Gram-positive pathogen that produces two primary virulence factors, enterotoxins A and B (TcdA and TcdB), which are responsible for Clostridium difficile-associated disease (CDAD) and are targets for CDAD therapy. Antibodies specific for TcdA and TcdB have been shown to effectively treat CDAD and prevent disease relapse in animal models and in humans. This review summarizes the various toxin-specific antibody formats and strategies under development, and discusses future directions for CDAD immunotherapy, including the use of engineered antibody fragments with robust biophysical properties for systemic and oral delivery.